Intravitreal ketorolac for chronic uveitis and macular edema: A pilot study

Archives of Ophthalmology

Volumn 130, Issue 4, 2012, Pages 456-460

  Kim, Stephen J ^a   Doherty, Terrence J ^b   Cherney, Edward F ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Loden Vision Centers   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; KETOROLAC;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; ELECTRORETINOGRAPHY; EYE DISEASE; HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINA MACULA EDEMA; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; UVEITIS; VISUAL FIELD;

AGED; AGED, 80 AND OVER; CHRONIC DISEASE; CYCLOOXYGENASE INHIBITORS; ELECTRORETINOGRAPHY; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; KETOROLAC TROMETHAMINE; MACULAR EDEMA; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; RETINA; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; UVEITIS; VISUAL ACUITY; VISUAL FIELD TESTS; VISUAL FIELDS;

EID: 84859953739     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archopthalmol.2011.2627     Document Type: Article

References (26)

1. Nussenblatt RB. The natural course of uveitis. Int Ophthalmol. 1990;14(5-6):303-308.
2. Suttorp-Schulten MS, Rothova A. The possible impact of uveitis in blindness: a literature survey. Br J Ophthalmol. 1996;80(9):844-848. (Pubitemid 26345317)
3. Bélair ML, Kim SJ, Thorne JE, et al. Incidence of cystoid macular edema after cataract surgery in patients with and without uveitis using optical coherence tomography. Am J Ophthalmol. 2009;148(1):128-135, e2. doi:10.1016/j.ajo.2009.02.029.
4. Kim SJ, Bressler NM. Optical coherence tomography and cataract surgery. Curr Opin Ophthalmol. 2009;20(1):46-51.
5. Johnson MW. Etiology and treatment of macular edema. Am J Ophthalmol. 2009;147(1):11-21, e1. doi:10.1016/j.ajo.2008.07.024.
6. Miyake K, Ibaraki N. Prostaglandins and cystoid macular edema. Surv Ophthalmol. 2002;47(suppl 1):S203-S218. (Pubitemid 35232234)
7. Kim SJ, Flach AJ, Jampol LM. Nonsteroidal anti-inflammatory drugs in ophthalmology. Surv Ophthalmol. 2010;55(2):108-133.
8. Rabiah PK, Fiscella RG, Tessler HH. Intraocular penetration of periocular ketorolac and efficacy in experimental uveitis. Invest Ophthalmol Vis Sci. 1996;37(4):613-618. (Pubitemid 26077681)
9. Margalit E, Kugler LJ, Brumm MV, et al. The safety of intraocular ketorolac in rabbits. Invest Ophthalmol Vis Sci. 2006;47(5):2093-2099. (Pubitemid 46768293)
10. Kim SJ, Adams NA, Toma HS, et al. Safety of intravitreal ketorolac and diclofenac: an electroretinographic and histopathologic study. Retina. 2008;28(4):595-605. (Pubitemid 351589569)
11. Barañano DE, Kim SJ, Edelhauser HF, Durairaj C, Kompella UB, Handa JT. Efficacy and pharmacokinetics of intravitreal nonsteroidal anti-inflammatory drugs for intraocular inflammation. Br J Ophthalmol. 2009;93(10):1387-1390.
12. Reddy R, Kim SJ. Critical appraisal of ophthalmic ketorolac in treatment of pain and inflammation following cataract surgery. Clin Ophthalmol. 2011;5:751-758.
13. Rezaei KA, Toma HS, Cai J, Penn JS, Sternberg P, Kim SJ. Reduced choroidal neovascular membrane formation in cyclooxygenase-2 null mice. Invest Ophthalmol Vis Sci. 2011;52(2):701-707.
14. Kim SJ, Lo WR, Hubbard GB III, et al. Topical ketorolac in vitreoretinal surgery: a prospective, randomized, placebo-controlled, double-masked trial. Arch Ophthalmol. 2008;126(9):1203-1208.
15. Soheilian M, Karimi S, Ramezani A, Peyman GA. Pilot study of intravitreal injection of diclofenac for treatment of macular edema of various etiologies. Retina. 2010;30(3):509-515.
16. Shen WY, Constable IJ, Chelva E, Rakoczy PE. Inhibition of diclofenac formulated in hyaluronan on angiogenesis in vitro and its intraocular tolerance in the rabbit eye. Graefes Arch Clin Exp Ophthalmol. 2000;238(3):273-282. (Pubitemid 30197964)
17. Durairaj C, Kim SJ, Edelhauser HF, Shah JC, Kompella UB. Influence of dosage form on the intravitreal pharmacokinetics of diclofenac. Invest Ophthalmol Vis Sci. 2009;50(10):4887-4897.
18. Kim SJ. Diagnosis and management of noninfectious pediatric uveitis. Int Ophthalmol Clin. 2011;51(1):129-145.
19. Monnier Y, Zaric J, Rüegg C. Inhibition of angiogenesis by nonsteroidal antiinflammatory drugs: from the bench to the bedside and back. Curr Drug Targets Inflamm Allergy. 2005;4(1):31-38. (Pubitemid 40584850)
20. Yanni SE, Barnett JM, Clark ML, Penn JS. The role of PGE2 receptor EP4 in pathologic ocular angiogenesis. Invest Ophthalmol Vis Sci. 2009;50(11):5479- 5486.
21. Hu W, Criswell MH, Ottlecz A, et al. Oral administration of lumiracoxib reduces choroidal neovascular membrane development in the rat laser-trauma model. Retina. 2005;25(8):1054-1064. (Pubitemid 44735104)
22. Sakamoto T, Soriano D, Nassaralla J, et al. Effect of intravitreal administration of indomethacin on experimental subretinal neovascularization in the subhuman primate. Arch Ophthalmol. 1995;113(2):222-226.
23. Kim SJ, Toma HS. Inhibition of choroidal neovascularization by intravitreal ketorolac. Arch Ophthalmol. 2010;128(5):596-600.
24. Maloney SC, Fernandes BF, Castiglione E, et al. Expression of cyclooxygenase-2 in choroidal neovascular membranes from age-related macular degeneration patients. Retina. 2009;29(2):176-180.
25. Chin MS, Nagineni CN, Hooper LC, Detrick B, Hooks JJ. Cyclooxygenase-2 gene expression and regulation in human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 2001;42(10):2338-2346. (Pubitemid 32848864)
26. Kim SJ, Toma HS, Barnett JM, Penn JS. Ketorolac inhibits choroidal neovascularization by suppression of retinal VEGF. Exp Eye Res. 2010;91(4):537-543.